MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-14-2025
Biomerica DPO Ratio 2011-2025 | BMRA
Annual DPO Ratio Biomerica
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 32.4 | 34.3 | 40.3 | 13.4 | 33.8 | 73.3 | 93.3 | 62.8 | 32.6 | 32.9 | 38 | 40.8 | 25.5 | 18.1 | 26.7 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 93.3 | 13.4 | 39.9 |
Quarterly DPO Ratio Biomerica
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.6 | 3.77 | - | - | 37.1 | 94.8 | 124 | 92.6 | 107 | 80.9 | 55.1 | - | - | - | 28.6 | 41.4 | 37.1 | 27.7 | 34.5 | 19.1 | 17.9 | 17 | 16.1 | 40.5 | 38.6 | 43.2 | 32 | 23.6 | 35.5 | 42.6 | 34.9 | 25.8 | 30.2 | 37.9 | 30.8 | 23.1 | 24.8 | 15.4 | 8.83 | - | 12.6 | 11.8 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 124 | 3.77 | 37.8 |
DPO Ratio of other stocks in the Diagnostics research industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
120 | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
21.3 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
125 | - | -61.36 % | $ 2.46 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
125 | $ 20.75 | -2.01 % | $ 223 M |  China |
 |
Co-Diagnostics
CODX
|
106 | $ 0.23 | -3.91 % | $ 6.75 M | USA |
 |
Biocept
BIOC
|
56.3 | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
52.5 | - | 0.22 % | $ 16.8 M | USA |
 |
Castle Biosciences
CSTL
|
52 | $ 39.22 | -0.44 % | $ 1.09 B | USA |
 |
Danaher Corporation
DHR
|
66.4 | $ 230.27 | -0.02 % | $ 168 B | USA |
 |
DarioHealth Corp.
DRIO
|
43.9 | $ 10.22 | 1.79 % | $ 290 M |  Israel |
 |
BioNano Genomics
BNGO
|
104 | $ 1.52 | -0.16 % | $ 1.93 M | USA |
 |
Exact Sciences Corporation
EXAS
|
139 | $ 101.55 | -0.02 % | $ 18.8 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
45.8 | - | - | $ 562 M |  Britain |
 |
DexCom
DXCM
|
70.4 | $ 68.16 | 0.87 % | $ 26.3 B | USA |
 |
Enzo Biochem
ENZ
|
52.3 | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
34.9 | $ 26.59 | -0.47 % | $ 804 M | USA |
 |
Global Cord Blood Corporation
CO
|
17.7 | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
61.4 | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
780 | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
43.5 | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
47.4 | - | -11.32 % | $ 2.94 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
8.98 | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
44.2 | $ 19.3 | -0.92 % | $ 1.04 B | USA |
 |
Heska Corporation
HSKA
|
39.7 | - | - | $ 1.31 B | USA |
 |
Anixa Biosciences
ANIX
|
1.29 K | $ 3.17 | -1.09 % | $ 101 K | USA |
 |
HTG Molecular Diagnostics
HTGM
|
112 | - | -20.0 % | $ 1.06 M | USA |
 |
IQVIA Holdings
IQV
|
126 | $ 226.44 | -0.21 % | $ 41.1 B | USA |
 |
Guardant Health
GH
|
83.6 | $ 102.14 | -0.82 % | $ 12.5 B | USA |
 |
Myriad Genetics
MYGN
|
42 | $ 6.4 | -1.31 % | $ 580 M | USA |
 |
ENDRA Life Sciences
NDRA
|
1.65 K | $ 4.66 | -8.27 % | $ 2.5 M | USA |
 |
Neogen Corporation
NEOG
|
62.7 | $ 7.27 | 1.89 % | $ 1.58 B | USA |
 |
Aspira Women's Health
AWH
|
112 | - | -6.19 % | $ 10.5 M | USA |
 |
National Research Corporation
NRC
|
10.1 | $ 18.6 | -0.35 % | $ 456 M | USA |
 |
Personalis
PSNL
|
67.3 | $ 8.14 | - | $ 482 M | USA |
 |
Quidel Corporation
QDEL
|
101 | $ 29.39 | 0.31 % | $ 1.24 B | USA |
 |
QIAGEN N.V.
QGEN
|
50 | $ 45.94 | 1.26 % | $ 10.2 B |  Niderland |
 |
Illumina
ILMN
|
56.3 | $ 134.51 | -0.33 % | $ 21.4 B | USA |
 |
Charles River Laboratories International
CRL
|
24.5 | $ 202.78 | -0.43 % | $ 10.4 B | USA |
 |
RadNet
RDNT
|
23.5 | $ 72.71 | -0.6 % | $ 5.31 B | USA |
 |
Soleno Therapeutics
SLNO
|
130 | $ 47.59 | -0.13 % | $ 1.91 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
18.3 | $ 175.65 | -0.16 % | $ 19.5 B | USA |
 |
Motus GI Holdings
MOTS
|
1.72 | - | -34.28 % | $ 263 K | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
33.1 | $ 253.7 | -0.07 % | $ 21.3 B | USA |
 |
ICON Public Limited Company
ICLR
|
6.52 | $ 181.2 | -0.9 % | $ 14.9 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
27 | $ 687.59 | -0.13 % | $ 56.7 B | USA |
 |
Lantheus Holdings
LNTH
|
25.3 | $ 67.17 | 0.69 % | $ 4.65 B | USA |